Exploring the potential of mRNA vaccines in combatting communicable and non-communicable diseases in low-income and lower-middle-income countries.

The global health landscape is increasingly dominated by a double burden of communicable diseases (CDs) and non-communicable diseases (NCDs), with low-income and lower-middle-income countries (LMICs) being disproportionately affected due to geographic, demographic, and socioeconomic vulnerabilities. While infectious diseases like HIV/AIDS, tuberculosis, malaria, and diarrheal illnesses continue to cause high mortality rates, particularly in LMICs, NCDs such as cardiovascular disease, cancer, diabetes, and chronic pulmonary conditions are rising rapidly due to demographic shifts and lifestyle changes. This dual burden not only contributes to high morbidity and mortality but also results in significant economic losses due to treatment costs and reduced productivity. World Health Organization projections suggest that by 2050, NCDs will account for 70% of all deaths in LMICs. This study aimed to explore recent literature on the impact of communicable diseases and NCDs in these regions and assess the potential role of mRNA vaccine technology in addressing this growing crisis. The findings indicate that mRNA vaccines have emerged as a transformative innovation in the field of vaccinology, offering rapid, adaptable platforms for addressing both infectious diseases and virus-induced cancers. The study highlights that mRNA vaccines could play a pivotal role in personalized and efficient disease management. However, barriers such as vaccine stability, cold-chain storage requirements, and delivery logistics hinder their implementation in resource-limited settings. This study emphasizes the need for targeted strategies to overcome these challenges and extend the benefits of mRNA vaccines to developing nations.